Figure 6
IL-10R expression is low or absent on the malignant T cells. (A) Representative flow cytometric analysis of IL-10 receptor (IL-10R) expression on the benign T-cell line, MF1850, and the malignant T-cell line, SeAx. (B) Representative flow cytometric analysis of IL-10R expression on benign (CD4+CD26+) and malignant (CD4+CD26−) T cells in PBMCs from an SS patient. (C) Graph showing the average percentage of IL-10R–positive benign (CD4+CD26+) and malignant (CD4+CD26−) T cells in PBMCs isolated from 5 SS patients. Bars represent SEM. FSC-H, forward scatter height; SSC-A, side scatter area.

IL-10R expression is low or absent on the malignant T cells. (A) Representative flow cytometric analysis of IL-10 receptor (IL-10R) expression on the benign T-cell line, MF1850, and the malignant T-cell line, SeAx. (B) Representative flow cytometric analysis of IL-10R expression on benign (CD4+CD26+) and malignant (CD4+CD26) T cells in PBMCs from an SS patient. (C) Graph showing the average percentage of IL-10R–positive benign (CD4+CD26+) and malignant (CD4+CD26) T cells in PBMCs isolated from 5 SS patients. Bars represent SEM. FSC-H, forward scatter height; SSC-A, side scatter area.

Close Modal

or Create an Account

Close Modal
Close Modal